Abstract:BACKGROUND: In a randomized trial, the early introduction of peanuts in infants at high risk for allergy was shown to prevent peanut allergy. In this follow-up study, we investigated whether the rate of peanut allergy remained low after 12 months of peanut avoidance among participants who had consumed peanuts during the primary trial (peanut-consumption group), as compared with those who had avoided peanuts (peanut-avoidance group).METHODS: At the end of the primary trial, we instructed all the participants to avoid peanuts for 12 months. The primary outcome was the percentage of participants with peanut allergy at the end of the 12-month period, when the participants were 72 months of age.RESULTS: We enrolled 556 of 628 eligible participants (88.5%) from the primary trial; 550 participants (98.9%) had complete primary-outcome data. The rate of adherence to avoidance in the follow-up study was high (90.4% in the peanut-avoidance group and 69.3% in the peanut-consumption group). Peanut allergy at 72 months was significantly more prevalent among participants in the peanut-avoidance group than among those in the peanut-consumption group (18.6% [52 of 280 participants] vs. 4.8% [13 of 270], P<0.001). Three new cases of allergy developed in each group, but after 12 months of avoidance there was no significant increase in the prevalence of allergy among participants in the consumption group (3.6% [10 of 274 participants] at 60 months and 4.8% [13 of 270] at 72 months, P=0.25). Fewer participants in the peanut-consumption group than in the peanut-avoidance group had high levels of Ara h2 (a component of peanut protein)-specific IgE and peanut-specific IgE; in addition, participants in the peanut-consumption group continued to have a higher level of peanut-specific IgG4 and a higher peanut-specific IgG4:IgE ratio.CONCLUSIONS: Among children at high risk for allergy in whom peanuts had been introduced in the first year of life and continued until 5 years of age, a 12-month period of peanut avoidance was not associated with an increase in the prevalence of peanut allergy. Longer-term effects are not known. (Funded by the National Institute of Allergy and Infectious Diseases and others; LEAP-On ClinicalTrials.gov number, NCT01366846.).

Peanut allergy in toddlers

Early Peanut Immunotherapy in Children (EPIC) trial: protocol for a pragmatic randomised controlled trial of peanut oral immunotherapy in children under 5 years of age

Optimising the management of peanut allergy by targeting immune plasticity

Successful introduction of peanut in sensitized infants with reported reactions at home

Peanut Allergy in Children—Is Prevention Better than Cure?

Desensitization And Remission After Peanut Sublingual Immunotherapy in 1- To 4-Year-Old Peanut-Allergic Children: A Randomized, Placebo-Controlled Trial

Effect of Avoidance on Peanut Allergy after Early Peanut Consumption

From Skin to Solution: Exploring Epicutaneous Immunotherapy for Peanut Allergy—A Systematic Review and Meta-Analysis

Food allergy: Epicutaneous immunotherapy

Diagnosing peanut allergy with skin prick and specific IgE testing

Current state and advances in desensitization for peanut allergy in pediatric age

Epitope-Specific IgE at 1 Year of Age Can Predict Peanut Allergy Status at 5 Years

Early Peanut Introduction in Primary Care: Evaluation of a Multicomponent Intervention

Cohort study of peanut and tree nut sensitisation by age of 4 years

Epicutaneous immunotherapy for the treatment of peanut allergy

Rates of New Peanut Allergy and Discontinuation Following Introduction in High-Risk Infants

Safety and feasibility of peanut, tree nut, and sesame oral immunotherapy in infants and toddlers in a real-world setting

Peanut immunotherapy provides long lasting suppression of allergy, finds study

Predicting reactivity threshold in children with anaphylaxis to peanut

The Risk Reduction of Accidental Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food Challenge Data After 1 Year of Peanut Oral Immunotherapy

Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy